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Background: Previous studies suggest elevated inﬂammation in schizophrenia and bipolar disorder, with in-
creased activity of the Interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor (TNF)-alpha, von
Willebrand factor (vWf) and osteoprotegerin (OPG). It is unclear how immune activation is involved in the
psychopathology. We investigated if elevated inﬂammation was associated with disease severity (trait) or
current symptom level (state), comparing psychotic with general characteristics.
Methods: Plasma levels of sTNF receptor 1 (sTNF-R1), IL-1 receptor antagonist (IL-1Ra), IL-6, vWf and OPG
were measured with ELISA techniques in 322 patients with schizophrenia spectrum and bipolar disorder.
Current symptom level (state) was measured with Global Assessment of Functioning (GAF) and Positive
and Negative Syndrome Scale (PANSS). Disease severity (trait) was measured with premorbid adjustment
scale (PAS), age at onset, number of psychotic episodes and number and length of hospitalizations.
Results: After controlling for confounders, IL-1Ra and TNF-R1 were independently associated with GAF, and
signiﬁcantly correlated with PANSS negative and positive, respectively. In addition, Il-1Ra was associated
with PAS, and sTNF-R1 with number of hospitalizations and psychotic episodes. VWf was signiﬁcantly corre-
lated with psychotic episodes, OPG with hospitalizations and IL-6 with history of psychosis. Linear regression
analysis showed that GAF remained associated with sTNF-R1 and IL-1Ra with PANSS, after controlling for the
other clinical measures.
Conclusions: This supports that inﬂammatory markers, particularly IL-1Ra and sTNF-R1 are associated with
both general disease severity and psychotic features. This supports a role of immune activation in the core
pathological mechanisms of severe mental disorders.© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
The underlying pathological mechanisms of severemental disorders
are still largely unknown. The disorders are highly heritable (Harrison
andWeinberger, 2005) with complex genetic and environmental inter-
actions involved (Burmeister et al., 2008). However, the speciﬁc
mechanisms involved remain elusive. Several lines of evidence have im-
plicated the immune system in the development of severe psychiatric
disorders (Watanabe et al., 2010) and inﬂammatory mediators are in-
volved in neurotransmission and cognition (McAfoose, 2009).ation, Oslo University Hospital,
-NC-ND license.Psychotic features are common to both schizophrenia and bipolar
disorder, although not all bipolar disorder patients have psychotic ep-
isodes (Jabben et al., 2009). Schizophrenia and bipolar disorder also
have similarities in genetic risk factors, which support the hypotheses
of a continuum (Williams et al., 2011). Several studies have reported
signs of systemic inﬂammatory activation in both schizophrenia and
bipolar disorder (Drexhage et al., 2011), although there has been
many inconsistent results(Schmitt et al., 2005; Freudenreich et al.,
2010; Kunz et al., 2011; Miller et al., 2011). According to a meta-
analysis there is fairly consistent evidence of raised activity in three
inﬂammatory pathways, the tumor necrosis factor (TNF), interleukin
1 (IL-1), and IL-6 (Drexhage et al., 2010). We previously reported a
signiﬁcant increase in sTNF receptor type 1 (sTNF-R1) and von
Willebrand factor (vWf) (Hope et al., 2009). The patients also had
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the TNF receptor superfamily related to calcium metabolism (Hope
et al., 2010). There was no signiﬁcant elevation of IL-6 or IL-1Ra, but
these markers were associated with affective state and severity of
depression in bipolar disorder (Hope et al., 2011).
Research into the relationship between immune factors and dis-
order characteristics in psychotic patient populations is sparse
(Goldstein et al., 2009; Miller et al., 2011). To the best of our knowl-
edge, there is no adequately powered study of associations between
inﬂammatory markers and disorder severity across schizophrenia
and bipolar disorder groups. Based on raised serum levels of sTNF,
IL-β and IL-6 in previous meta-analysis, and our ﬁndings of elevated
OPG and vWf in schizophrenia and bipolar disorders, we examined
if activities in these pathways were associated with severity of the
mental disorders. High cytokine levels may be a trait inﬂuenced by
genetic factors (Raﬁq et al., 2007; Clerici et al., 2009; Vistoropsky
et al., 2010), and thus inﬂuence stable disease characteristics. In addi-
tion, cytokine levels may be affected by acute physical and mental
challenges, and thus ﬂuctuate in relation to stressors (Kop et al.,
2008; Brydon et al., 2009). A cross-sectional study with no direct
follow-up of disease characteristics related to ﬂuctuations of immune
markers in the individual has clear limitations concerning inferences
about causality or direction of effect, but can provide valuable de-
scriptive information. We investigated if inﬂammatory markers are
associated with severity of psychotic disorders in an adequately
powered study across both schizophrenia and bipolar disorder groups
in the same sample of patients as in our previous studies (Hope et al.,
2009, 2010). The hypothesis was that high levels of inﬂammation
would be associated with more severe clinical symptom levels
(state) and with a more severe disease history (traits).
2. Methods
2.1. Participants
The study population has previously been reported in detail (Hope
et al., 2009). Brieﬂy, patients were included through referrals to the
ongoing Thematically Organized Psychosis (TOP) Study in Oslo,
Norway (for details, see Birkenaes et al., 2007).
Inclusion criteria: being registered in the psychiatric services of any
one of the four University Hospitals in Oslo; age 18 to 65 years;meeting
DSM-IV criteria for schizophrenia or bipolar spectrum disorders.
Exclusion criteria: history of moderate or severe head injury, neu-
rological disorder, mental retardation, malignancies and acute or
chronic infectious disorders. The patients were included between
2003 and 2008. We do not have a precise number of all eligible pa-
tients, but the fraction of eligible patients that declined to participate
or were not included for other reasons was 13%. Due to IRB regula-
tions we could not collect information from the patients who declined
to participate. However, previous analysis based on hospital charts
from all treated psychotic patients found no signiﬁcant difference be-
tween the study sample and the clinical hospital sample regarding ill-
ness severity and sociodemographic variables and substance abuse
(Ringen et al., 2008). Included in the current analyses were consecu-
tive referred patients with valid measurements of inﬂammatory
markers, without any use of immunomodulating drugs including
non-steroid anti-inﬂammatory drugs or statins, consisting of a total
of 322 patients (192 had a DSM-IV non affective psychotic disorder,
comprising schizophrenia [n=147], schizophreniform [n=11] and
schizoaffective disorder [n=34], 130 had a bipolar spectrum disorder
(Bipolar I disorder [n=77], Bipolar II disorder [n=45] and Bipolar
not otherwise speciﬁed [n=8]). One patient had missing data regard-
ing IL-1Ra and OPG. All participants gave written informed consent to
participation including the permission to re-use the data for further
analysis, and the study has been approved by the Regional Committee
for Medical Research Ethics and the Norwegian Data Inspectorate.2.2. Study design
We explored if markers of inﬂammation were associated with the
current clinical severity (state) or history of disease severity (trait) of
both general and psychotic characteristics in a cross-sectional study.
We used Global Assessment of Functioning; (GAF) (Greenberg and
Rosenheck, 2005; Aas, 2010) as measure of general state, and Positive
and Negative Syndrome Scale; (PANSS) (Santor et al., 2007) as mea-
sure of psychotic state. General traits was measured with premorbid
adjustment scale (PAS) (Brill et al., 2008), age at onset of ﬁrst episode
and number and length of hospitalizations and psychotic traits with
history of psychosis, age at ﬁrst psychotic episode and number of psy-
chotic episodes.
2.2.1. Confounding factors
We included age, gender, ethnicity, smoking, alcohol intake, kidney
and liver function, having a diagnosis of autoimmune disorder, hyper-
tension, high-sensitivity C-reactive protein (hsCRP), medication with
antipsychotics, mood stabilizers and antidepressants as confounders.
2.3. Assessments
All patients were assessed by trained clinical research personnel
(psychiatrists and clinical psychologists). The Structured Clinical
Interview for DSM-IV Axis I Disorders (SCID-I) was used for diagnos-
tic purposes, and global symptomatology and functioning was mea-
sured by the GAF Scale (split version). Inter-rater reliability was
good, with an overall kappa score of 0.77 (95% conﬁdence interval:
0.60–0.94) for diagnoses and an ICC (1.1) of 0.86 for both symptom
and function GAF scores, and 0.73, 0.73 and 0.71 for PANSS positive,
negative and general subscales respectively. PANSS is a commonly
used scale to measure symptoms in psychotic disorders (Kay et al.,
1987). For all participants, daily smoking, the use of alcohol and
drugs during the last 2 weeks prior to assessment was recorded.
2.4. Biochemical and Immunological measures
Blood sampling was performed between 8 am and 14 pm. The
analysis of clinical chemistry parameters was performed at Depart-
ment of Clinical Chemistry, Oslo University Hospital, Oslo, Norway
on an Integra 800 from Roche Diagnostics (Basel, Switzerland) using
standard methods. For immunological analysis, blood was drawn on
EDTA vials, and plasma was extracted the next workday and stored
at −80 °C. The methods for the measurements of plasma levels of
sTNF-R1, IL-1Ra, OPG, vWf and hsCRP as well as the results from
these measurements in the present study population have previously
been reported (Hope et al., 2009, 2010), using enzyme immunoassays
(EIA) obtained from R&D Systems, Minneapolis, MN (sTNFR1, IL-1Ra,
OPG) or an EIA using antibodies from DakoCytomation (Oslo,
Norway; vWf) (Bollerslev et al., 2006). In the vWf analyses, levels
are given in plasma concentration percent (%) and the standard
curve is based on samples from a plasma pool of healthy individuals,
where the normal range is set to 70–130%. All intra- and inter-assay
coefﬁcients of variance were b10%.
2.5. Statistical procedures
All statistical analyses were done using the SPSS software package
for Windows version 15.0 (SPSS, Chicago, IL). Bipolar disorder and
schizophrenia were merged for the main analysis, and sub analyses
were done for schizophrenia spectrum and bipolar disorder indepen-
dently. All tests were two-sided with a preset level of signiﬁcance of
0.05. Correlation tests were done by both Spearman's Rho and
Pearson's dependent on the distribution of data. Regarding IL-1Ra,
there were signiﬁcant associations with both methods, and we
reported the Pearson correlations, as these associations tended to be
Table 1
Demographics.
All Patients
n=322
Schizophrenia
n=192
Bipolar
disorder
n=130
Age (years) 34 (11) 33.6 (12) 35.5 (12)
Gender (female) 51% 43% 63%*
European (white) 82% 77% 90%*
Years of education 13 (3) 12 (3) 14 (3)*
Creatinine (μmol/l) n=307 71 (15) 71 (13) 71(17)
ALAT (U/l) (n=311) 29 (20) 30 (19) 27 (21)
Diabetes/hypertension 5% 5% 5%
Alcohol use (units) (n=310) 9 (20) 7 (17) 13 (23)*
Smoking (n=315) 56% 58% 53%
GAF-Symptoms 48 (14) 41 (11) 59 (11)*
GAF-Function 48 (13) 42 (10) 57 (12)*
PANSS positive 13 (6) 15 (6) 10 (3)*
PANSS negative 13 (6) 16 (6) 10 (4)*
PANSS general 29 (8) 63 (16) 45 (10)*
Current psychosis 39% 60% 8.4%*
History of psychosis 83% 100% 57%
No of psychotic episodes (n=242) 3.0 (4) 3.2 (4.6) 2.3 (2.2)*
Hospital admissions (n=238) 4.0 (4.7) 4.5(5.1) 2.9 (3.6)*
Age of onset 24 (9) 25 (9) 23 (10)
Duration of disorder 9 10 9
Antipsychotic medication 71% 88% 45%*
Mood stabilizer 35% 21% 57%*
Antidepressants 38% 35% 40%
Medication free 9% 7% 11%
Mean (Standard deviation) or percent is presented. ALAT; alanine aminotransferase,
Alcohol use: number of alcohol units (10 ml alcohol) during the last 2 weeks. GAF;
General Assessment of Functioning, split version, PANSS; Positive and Negative
Syndrome Scale; Current psychosis; A score on PANSS items P1,P3, P5, P6 or G9 ≥4 Age
at onset; age at the ﬁrst episode of depression, mania or psychosis according to criteria
in DSM-IV.*=signiﬁcant difference between bipolar and schizophrenia group, pb0.05.
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no linear correlations, only non-parametrical.
2.5.1. Multiple testing
We did 13 tests for each of the 5 inﬂammatory markers. To reduce
the probability of chance ﬁndings, we did a family-wise error rate
Bonferroni correction, with a signiﬁcance threshold at p=0.00038.
In addition we calculated the cumulative probability of that a number
of signiﬁcant associations would occur by chance.
2.5.2. Confounding factors
Inﬂammatorymarker levels could be inﬂuenced by confounders and
we analyzed the following factors: age, gender, ethnicity, smoking, alco-
hol intake, kidney and liver function, having a diagnosis of autoimmune
disorder, hypertension, high-sensitivity C-reactive protein (hsCRP),
time of blood sampling, medication with antipsychotics, mood stabi-
lizers and antidepressants. Control for confounders was done by ﬁrst
analyzing which of the possible confounders were correlated with
the immune markers, i.e. Pearson correlation coefﬁcient r>0.05 and
pb0.1. The factors that correlated with immune markers were
controlled for by doing linear regression analysis. In a ﬁnal model, we
controlled for all the possible confounding factors, regardless if the fac-
tors were correlatedwith immunemarkers or not, including control for
medication with antipsychotics, mood stabilizers and antidepressants.
2.6. Regression analysis regarding correlations between variables
Although general symptoms and psychotic symptoms are regarded
different clinical characteristics, they may overlap to some extent.
Thus, we analyzed the Pearson correlation coefﬁcient between state
and trait measures. Regression analysis with co-linearity analysis
was done to ﬁnd out whether clinical severity measures were inde-
pendently associated with inﬂammatory markers. We also analysed
the correlation between the inﬂammatory markers, and regression
analysis was done if two or more inﬂammatory markers were corre-
lated with the same clinical severity measure. Only patients with psy-
chotic episodes were included in the analyses of age at onset of
psychosis and number of psychotic episodes.
3. Results
3.1. Patient characteristics are listed in Table 1
3.1.1. Correlations with possible confounding factors
Bivariate analysis showed that sTNF-R1 was correlated with age,
smoking, having a diagnosis of diabetes or hypertension, autoimmune
disorder, kidney function (creatinine) andwith hsCRP. IL-1Rawas cor-
related with age, gender, time of blood sampling, smoking and having
a diagnosis of diabetes or hypertension. VWf was correlated with age,
gender, European ethnicity, autoimmune disorder and creatinine.
High-sensitivity C-reactive protein (hsCRP) was included as a pos-
sible confounder of peripheral infection, although hsCRP was not sig-
niﬁcantly correlated with any of the disease characteristics.
Clinical state measures were correlated with each other, and the
highest Pearson coefﬁcient was between GAF-f and GAF-s (r=0.83).
Both GAF-s and GAF-f correlated with PANSS positive (r=-0.71 and
r=−0.55) and PANSS negative (r=−0.52 and r=−0.53). The
strongest correlation between clinical trait measures was between
number of psychotic episodes and number of hospital admissions
(r=0.64), pb0.001 for all.
3.1.2. Whole sample correlations between inﬂammatory markers and
general disease severity measures
3.1.2.1. General state (Table 2). sTNF-R1 and IL-1Ra was associated
with poorer function (GAF-f) (p=0.001 and p=0.003 respectively).The associations remained signiﬁcant after controlling for possible
confounders (see Methods) (p=0.002 for sTNF-R1 and p=0.03
for IL-1Ra). A common regression analysis for predicting GAF-f
showed that both sTNF-R1 and IL-1Ra were independent predictors
(p=0.005 and p=0.02). As for the other markers (OPG, vWf and
IL-6) no associations were found with any of state variables (Table 2).
3.1.2.2. General trait (Table 2). IL-1Ra was associated with PAS late
adolescence and PAS adulthood (p=0.009 and 0.007 respectively),
which was signiﬁcant also after controlling for confounders (p=0.048
for both). In those who had been admitted to hospital, sTNF-R1 was
associated with number and length of hospitalizations (p=0.001 for
both) which was signiﬁcant after controlling for confounders (p=
0.02). As for the other inﬂammatory markers (OPG, vWf and IL-6), the
only signiﬁcant correlation with trait markers was a weak but signiﬁ-
cant correlation of OPG with number of hospitalizations (Table 2).
3.1.3. Whole sample correlations between inﬂammatory markers and
psychotic measures
3.1.3.1. Psychotic state (Table 3). The associations between sTNF-R1 and
currently being in a psychotic state and the level of PANSS positive
symptoms were still signiﬁcant after controlling for confounders (p=
0.012 and p=0.03, respectively).These correlations did not remain sta-
tistically signiﬁcant when patients without psychosis were excluded
(n=265, r=0.11, p=0.09 for PANSS positive, and r=0.10, p=0.13
for present psychosis). IL-1Ra was associated with severity of PANSS
negative symptoms which remained signiﬁcant after controlling for
confounders (p=0.001, n=314) and when patients without previous
psychosis were excluded (r=0.18, p=0.006, n=257). OPG, vWf and
IL-6, were not correlated with any of the psychotic state markers
(Table 3).
Table 4
Regression model for prediction of GAF functioning.
Table 2
Pearson correlation coefﬁcients between general disease severity measures and immune
markers.
sTNF-R1 IL-1Ra OPG vWf IL-6
State
GAF-function (n=322) −0.18⁎⁎a −0.16⁎⁎a 0.06 −0.07 −0.05
GAF-symptoms (n=322) −0.11⁎a −0.10 0.06 −0.03 −0.01
PANSS general (n=321) −0.01 0.13⁎ −0.08 0.02 −0.03
Trait
Age at onset 0.07 −0.09 0.05 0.08 0.02
PAS late adulthood (n=276) −0.02 0.16⁎⁎a −0.03 0.08 −0.003
Number of hospitalizations
(n=238)
0.22⁎⁎a 0.04 0.14⁎ 0.10 0.13b
Duration of hospitalizations
(n=232)
0.23⁎⁎a,b 0.10 0.09 0.11 0.09b
Pierson correlation coefﬁcients are given for all parameters except IL-6, were Spearman
Rho is reported. GAF; General Assessment of Functioning, split version (F; function, S;
symptoms), PANSS; Positive and negative syndrome scale, PAS; total score on Premorbid
Assessment of Functioning. sTNF-R1; soluble Tumor Necrosis Factor – R1, IL-1Ra, Interleu-
kin 1 receptor antagonist; OPG, osteoprotegerin; vWf: von Willebrand factor.
⁎ pb0.05.
⁎⁎ pb0.01.
a Signiﬁcant correlation in the schizophrenia subsample.
b Signiﬁcant correlation in the bipolar subsample.
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sociated with having a lifetime psychotic episode (Table 3) also after
controlling for confounders (p=0.03, p=0.02, p=0.02, p=0.02, re-
spectively), while the association of IL-1Ra with age at onset of psy-
chosis lost its signiﬁcance after controlling for confounders (p=0.11).
3.1.4. Multiple testing
There were 16 signiﬁcant associations out of the 13×5=65 tests
performed. The cumulative probability of ﬁnding this by chance is
p=1×10−8. For TNF-R1, 8 out of 13 testswere signiﬁcant, and the like-
lihood of this being a chance ﬁnding is p=1×10−9. For IL-1Ra, 6 out of
13 tests were signiﬁcant, with p=1×10−6 for being chance ﬁnding.
The signiﬁcance threshold after family-wise error rate Bonferroni cor-
rection was p=0.004. After correction sTNF-R1 remained signiﬁcantly
associated with GAF-f (p=0.001), number of hospital admissions
(p=0.001) and with length of hospital stays (p=0.001), and IL-1Ra
remained signiﬁcantly associated with PANSS negative symptoms
(p=0.00009).Table 3
Correlation coefﬁcients between immune markers and clinical severity measures of
psychosis.
TNF-R1 IL-1Ra OPG vWf IL-6
State
Current psychosis (n=322) 0.13⁎a 0.03 −0.003 −0.001 0.06
PANSS Positive (n=322) 0.13⁎ 0.08 0.05 0.005 0.04
PANSS Negative (n=322) 0.02 0.22⁎⁎ −0.09 0.10b −0.05
Trait
Psychosis life time
(n=321)
0.13⁎,b 0.15⁎⁎b −0.02 0.11⁎ 0.12⁎,b
Age at onset of psychosisy
(n=256)
0.06 −0.14⁎ 0.11 0.03 0.04
Number of psychotic
episodesy (n=242)
0.19⁎⁎a,b 0.02 0.09 0.17⁎⁎ 0.07
Pierson correlation coefﬁcients are given for all parameters except IL-6, were Spearman
Rho is reported. One patient is missing regarding IL-1Ra and OPG. PANSS: Positive and
negative syndrome scale, Current psychosis: PANSS items P1, P3, P5, P6 or G9.≥4,
TNF-R1: soluble Tumor Necrosis Factor-R1, IL-1Ra: Interleukin 1 receptor antagonist,
OPG: osteoprotegerin; vWf: von Willebrand factor; IL-6: interleukin 6.
bSigniﬁcant correlation in the bipolar subsample y=only patients with a history of
psychosis were included.
⁎ pb0.05.
⁎⁎ pb0.01.
a Signiﬁcant correlation in the schizophrenia subsample.3.1.5. Regression analysis regarding clinical measures and sTNF-R1 and
IL-1Ra
Linear regression analysis showed that GAF-f was the clinical
severity measure with the highest independent association with
TNF-R1 in the whole sample, and TNF-R1 was signiﬁcantly predictive
of GAF-f also when 17 possible confounding factors were controlled
for (Table 4). PANSS negative symptoms was the clinical severity
measure that showed the highest independent association with
IL-1Ra and IL1-Ra was predictive of PANSS negative symptoms
when 18 possible confounding factors were controlled for (Table 5).3.1.6. Correlations within the schizophrenia and bipolar disorders
diagnostic groups
We examined if our correlations were signiﬁcant also in the two
diagnostic subgroups separately (Tables 2 and 3).3.1.6.1. Schizophrenia. The following correlations were signiﬁcant also
after controlling for confounders sTNF-R1 with GAF-f (p=0.007),
GAF-s (p=0.04) and currently being psychotic (p=0.004). IL1Ra
was correlated with GAF-f (p=0.04) and PANSS negative symptoms
(p=0.02). VWf was signiﬁcantly associated with PANSS negative
symptoms (p=0.03).3.1.6.2. Bipolar disorder. There were no signiﬁcant correlations be-
tween clinical state variables and inﬂammatory markers but there
was a non-signiﬁcant trend similar to that seen in schizophrenia of a
correlation between sTNF-R1 and GAF-function (r=-0.13, p=0.16),
and between IL-1Ra with negative symptoms (r=0.13, p=0.15).
The following correlations were signiﬁcant also after controlling for
confounders. STNF-R1 was correlated with length of hospital stays
(p=0.04). IL-6 was correlated with length of hospitalization (p=
0.04) and with history of psychosis (p=0.02). Il-1Ra was correlated
with history of psychosis (p=0.03). VWfwas correlatedwith number
of psychotic episodes in patients with a previous psychotic episode
(p=0.02). OPG showed no signiﬁcant correlations with these trait
variables after controlling for confounders (data not shown).B t Signiﬁcance
Constant 30.25 4.28 b0.01⁎⁎
Age −0.03 −0.35 0.73
Gender 3.44 2.05 0.04⁎
Ethnic White 4.75 2.58 0.01⁎
Smoking −1.92 −1.31 0.19
Alcohol 0.01 0.13 0.89
Drug abuse 0.12 0.22 0.82
Diabetes/CVD 1.28 0.39 0.69
Autoimmune disease 0.08 0.06 0.95
HsCRP −0.12 −0.33 0.74
Creatinine 0.05 0.89 0.38
ALAT 0.02 0.41 0.68
Cholesterol −1.10 −1.58 0.12
Glucose 0.74 1.35 0.18
Antipsychotics −2.02 −1.19 0.23
Mood stabilizing 0.56 0.35 0.73
Antidepressive −1.19 −0.84 0.40
Diagnostic category 11.82 6.98 b0.01⁎⁎
TNF-R1 −5.55 −2.31 0.02⁎
Diabetes/CVD=Diabetes or cardiovascular disease; Alcohol: No of units drunk last
two weeks; Substance abuse=use of illegal drugs last 2 weeks. ALAT=alanine
aminotransferase; hsCRP=high sensitivity C - reactiveprotein; Antipsychotic=medicated
with antipsychotics or not; Mood stabilizing=medicated with mood stabilizing agent;
Antidepressive=medicated with antidepressive agent; sTNF-R1; soluble tumor necrosis
factor receptor 1.
⁎ pb0.05.
⁎⁎ pb0.01.
Table 5
Regression model for prediction of PANSS negative symptoms.
B T Sig
Constant 20.97 4.76 b0.01
Age −0.03 −0.93 0.35
Gender −2.02 −2.93 b0.01*
Ethnic White 0–.46 0–.57 0.57
Smoking 0.70 1.11 0.27
Alcohol −0.02 −1.53 0.13
Drug abuse −0.20 −0.78 0.43
Diabetes/CVD −1.61 −1.10 0.27
Autoimmune disease 0.02 0.04 0.97
hsCRP −0.14 −0.88 0.38
Creatinine −0.01 −0.48 0.63
ALAT 0.00 −0.60 0.55
Cholesterol 0.33 1.07 0.29
Glucose −0.05 −0.21 0.83
Antipsychotics 0.86 1.19 0.24
Mood stabilizing 0.11 0.17 0.87
Antidepressive 1.54 2.51 b0.01*
Diagnostic category −4.13 −5.80 b0.01*
Time of blood sampling 0.06 0.19 0.85
IL-1Ra 0.83 2.85 0.005*
Diabetes/CVD=Diabetes or cardiovascular disease; Alcohol: No of units drunk last two
weeks; Substance abuse=use of illegal drugs last 2 weeks. ALAT=alanine
aminotransferase; hsCRP=high sensitivity C-reactive protein; Antipsychotic=
medicated with antipsychotics or not; Mood stabilizing=medicated with mood
stabilizing agent; Antidepressive=medicatedwith antidepressive agent; IL-1Ra=soluble
Interleukin 1 receptor antagonist.
* pb0.05.
** pb0.01.
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The main ﬁnding of the present study was a signiﬁcant association
between clinical severity and levels of sTNF-R1 and IL-1Ra in psychot-
ic disorders, including both state and trait characteristics of a general
and speciﬁc (psychotic) nature. After Bonferroni correction for multi-
ple testing, and control for interaction and confounders, TNF-R1
remained signiﬁcantly correlated with general function and IL-1Ra
remained signiﬁcantly correlated with PANSS negative symptoms.
The results were consistent in that high levels of these two markers
were correlated with more severe characteristics as indicated by
lower general function scores, age at onset, and premorbid adjust-
ment measures, and by higher number and durations of disorder
episodes, and higher current symptom levels. This may indicate a
role of inﬂammation and in particular the TNF and IL-1 pathways in
psychotic disorders and suggests their involvement in both develop-
ment aspects and in ongoing ﬂuctuations in psychopathology.
CRP is a reliablemarker of inﬂammation, but it is unlikely that it re-
ﬂects all pathways in this complex process. One reason is that hsCRP is
made by the liver and is too large to pass the BBB (Hsuchou et al.,
2012), while TNF-R1 and IL-1Ra is expressed by neurons in the brain
(Tchelingerian et al., 1993). Our ﬁndings showing that sTNF-R1 and
IL-1Ra were correlated with disease characteristics also after
correcting for hsCRP further support such a notion.
Several studies and meta-analyses have found evidence of elevated
levels of TNF-α in schizophrenia, bipolar disorder and major
depression (Dowlati et al., 2010; Drexhage et al., 2010), and a
previous smaller study also reported that TNF-α was correlated with
positive psychotic symptoms (Erbaægci et al., 2001). In our sample,
TNF-R1 is the only inﬂammatory marker that was both highly signiﬁ-
cantly elevated compared to controls, as well as associated with several
clinical severitymeasures. This supports that TNF-R1 is a central inﬂam-
matory marker in severe mental disorders.
As for IL-1Ra, no previous studies have investigated if serum levels of
this marker are associated with negative symptoms (Drexhage et al.,
2010), but an association between negative symptoms and IL-1Ra
(Sirota et al., 2005) and between the polymorphisms in the IL-Ra geneand negative symptoms (Mata et al., 2006) have been reported, which
seem to support the current results.
However, it is puzzling that IL-1Ra is associated with symptom se-
verity, as the average IL-Ra levels in these patients are not different
from controls (Hope et al., 2009). This may indicate some disease-
speciﬁc effects related to pathological regulation of mood and reality
monitoring. There are several lines of evidence supporting disease
speciﬁc effects on biological processes in severe mental disorders
(Prata et al., 2009; Wirgenes et al., 2010). Further, our ﬁnding may
also indicate a subgroup of patients being strongly affected, and
others well within the range of healthy controls.
One explanation for the lack of association between TNF and IL-1
to trait markers in previous studies (Drexhage et al., 2010) could be
low statistical power, as our study included a larger number of pa-
tients. Another explanation might be that Il-1Ra and sTNF-R1 are
more stable markers than IL-1β and TNF-α themselves (Gu et al.,
2009). Both TNF-α and in particular IL-1β circulate at very low levels,
just above the detection limit of the various EIAs. And although
TNF-R1 and IL-1Ra can antagonize IL-1 and TNF activity, circulating
levels of Il-1Ra and sTNF-R1 are regarded as stable and reliable
markers of the activity in the IL-1 and TNF system (Diez-Ruiz et al.,
1995; Spulber et al., 2009). Moreover, it has been suggested that
IL-1Ra itself should be regarded as an acute phase response as both
IL-1β and IL-6, both inducers of CRP, are strong inducers of IL-1Ra in
humans (Gabay et al., 1997).
The current ﬁndings show similar immune proﬁle in bipolar disor-
der and schizophrenia and seem to support the view that these disor-
ders have some common pathological mechanisms. However, our
ﬁndings also show some differences as sTNF-R1 and IL-1Ra were in-
dependently associated with clinical state measures in patients with
schizophrenia; this was not signiﬁcant in bipolar disorders. In both bi-
polar disorder and schizophrenia, the inﬂammatory markers were in-
dependently associated with trait measures. Thus, we could speculate
that the inﬂammatory factors are associated with trait related mea-
sures in both disorders due to some shared genetic susceptibility,
and that they may be associated with affective state in bipolar disor-
der, and with psychotic state in schizophrenia. The reason for the dif-
ferent pattern in schizophrenia and bipolar disorders is not clear, but
might partly be explained by the lower level of psychotic symptoms
in bipolar disorder. In the current study, 57% of the bipolar disorder
patients have experienced a psychotic episode, which is equal to the
frequency (58%) reported in a meta-analysis (Goodwin and Jamison,
1990). However, 8.4% of those who had been psychotic were current-
ly in a psychotic state, which is somewhat lower than the 14% found
in the meta-analysis (Goodwin and Jamison, 1990). The prevalence
of current psychosis in the schizophrenia patients was much higher
(60%), and equal to a previous study (Eberhard et al., 2009). The rel-
atively low percentage of psychotic bipolar disorder patients may
have reduced the statistical power to ﬁnd associations, and thus the
difference between schizophrenia and bipolar disorder should be
interpreted with caution.
The biological mechanisms responsible for the associations between
disease severity and sTNF-R1 and IL-1Ra are not known. However, ani-
mal studies have found that IL-1Ra increases as a response to social
withdrawal (Bluthâe et al., 1997; Rohleder et al., 2006; Arakawa et al.,
2009; Norman et al., 2010), which is a core item of PANSS negative
symptoms. Furthermore, both animal and human studies have found
that elevated TNF induces cognitive disturbances (Jiang et al., 2011;
Yirmiya and Goshen, 2011; Belarbi et al., 2012), and cognitive disorga-
nization is an item of PANSS positive scale. Both sTNF-R1 and IL-1Ra
are also affected by dopamine (Gomez-Santos et al., 2007; Koprich
et al., 2008), and it is possible that inﬂammatory interactionswith dopa-
mine neurotransmission is an underlying mechanism of the present
ﬁndings.
At present, there are no direct clinical implications of the current
results, mainly because we do not know the cause of the elevated
41S. Hope et al. / Schizophrenia Research 145 (2013) 36–42inﬂammation. Patients have elevated frequency of both autoimmune
diseases and neurotropic infections (Eaton et al., 2010; Chen et al.,
2012a), and both anti-inﬂammatory and anti-infective drugs have
been reported to be beneﬁcial as adjunctive medication (Chaudhry
et al., 2012; Prasad et al., 2012; Sommer et al., 2012). It has also
been reported that antipsychotic and mood stabilizing medications
have immunomodulating properties (Drzyzga et al., 2006; Chen
et al., 2012b; Nahman et al., 2012), and further research is needed
to elucidate if these drugs may inﬂuence IL-1, TNF and other inﬂam-
matory pathways.
The major limitation of the current study is the cross-sectional na-
ture with no possibility to investigate disease characteristics related
to ﬂuctuations of inﬂammatory markers in the individual. This
makes it impossible to draw conclusions about causal relationships.
The correlation coefﬁcients between inﬂammation and disease char-
acteristics were in the 0.1–0.26 range, explaining only around 1–7%
of the variance in severity. However, the current correlation range is
similar to results in previous studies of inﬂammation and psychiatric
symptoms (Chadwick et al., 2008; Zhang et al., 2008; Orre et al.,
2009). Furthermore, the patients in the current sample are young
and well functioning, and it is possible that investigations of samples
with a larger variation in severity could lead to higher correlation
coefﬁcients.
Our study shows that serum levels of sTNF-RI and IL-1Ra were
correlated tomore severe symptom states and disorder traits, both gen-
eral and psychotic, in patientswith schizophrenia and bipolar disorders.
This extends previous reports of inﬂammatory markers in severe men-
tal disorder, and may suggest an involvement of inﬂammation in both
state and trait related pathophysiological mechanisms. Further studies
are needed to replicate the current ﬁndings and such studies should in-
clude a longitudinal design.
Role of funding source
The study was supported by a grant to the TOP study group from the University of
Oslo, the Research Council of Norway (#167153/V50, #163070/V50), and the South-East
Norway Health Authority (#2004123, #2007050). The funding source did not have any
role in the study design, theinterpretation of data or in thepublication of study.
Contributors
Drs. Hope and Andreassen conceived the study and its design and acquired and
analysed the data. Drs. Aukrust and Ueland contributed to the study conception and
the analysis and interpretation of data. Drs. Hope, Dieset, Berg,Steen, Lorentzen, and
Agartzcontributed to data acquisition. Drs. Hope and Andreassen wrote the manu-
script, which was reviewed by all other authors. All authors approved the ﬁnal version
submitted forpublication.
Conﬂict of interest
No authors reported any biomedical ﬁnancial interests or potential conﬂicts of
interest relevant to the subject matter of the manuscript.
Acknowledgements
The authors thank the patients and controls for participating in the study, and TOP
study group members for contributing with data collection.
References
Aas, I.M., 2010. Global Assessment of Functioning (GAF): properties and frontier of
current knowledge. Ann. Gen. Psychiatry 9, 20.
Arakawa, H., Blandino Jr., P., Deak, T., 2009. Central infusion of interleukin-1 receptor
antagonist blocks the reduction in social behavior produced by prior stressor expo-
sure. Physiol. Behav. 98 (1–2), 139–146.
Belarbi, K., Jopson, T., Tweedie, D., Arellano, C., Luo, W., Greig, N.H., Rosi, S., 2012. TNF-
alpha protein synthesis inhibitor restores neuronal function and reverses cognitive
deﬁcits induced by chronic neuroinﬂammation. J. Neuroinﬂammation 9, 23.
Birkenaes, A.B., Opjordsmoen, S., Brunborg, C., Engh, J.A., Jonsdottir, H., Ringen, P.A.,
Simonsen, C., Vaskinn, A., Birkeland, K.I., Friis, S., Sundet, K., Andreassen, O.A.,
2007. The level of cardiovascular risk factors in bipolar disorder equals that of
schizophrenia: a comparative study. J. Clin. Psychiatry 68 (6), 917–923.
Bluthâe, R.M., Dantzer, R., Kelley, K.W., 1997. Central mediation of the effects of interleukin-1
on social exploration and body weight in mice. Psychoneuroendocrinology 22 (1),
1–11.
Bollerslev, J., Ueland, T., Jorgensen, A.P., Fougner, K.J., Wergeland, R., Schreiner, T.,
Burman, P., 2006. Positive effects of a physiological dose of GH on markers ofatherogenesis: a placebo-controlled study in patients with adult-onset GH deﬁ-
ciency. Eur. J. Endocrinol. 154 (4), 537–543.
Brill, N., Reichenberg, A., Weiser, M., Rabinowitz, J., 2008. Validity of the premorbid
adjustment scale. Schizophr. Bull. 34 (5), 981–983.
Brydon, L., Walker, C., Wawrzyniak, A., Whitehead, D., Okamura, H., Yajima, J., Tsuda, A.,
Steptoe, A., 2009. Synergistic effects of psychological and immune stressors on in-
ﬂammatory cytokine and sickness responses in humans. Brain Behav. Immun. 23
(2), 217–224.
Burmeister, M., McInnis, M.G., Zollner, S., 2008. Psychiatric genetics: progress amid
controversy. Nat. Rev. Genet. 9 (7), 527–540.
Chadwick, W., Magnus, T., Martin, B., Keselman, A., Mattson, M.P., Maudsley, S., 2008.
Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci. 31 (10),
504–511.
Chaudhry, I.B., Hallak, J., Husain, N., Minhas, F., Stirling, J., Richardson, P., Dursun, S.,
Dunn, G., Deakin, B., 2012. Minocycline beneﬁts negative symptoms in early
schizophrenia: a randomised double-blind placebo-controlled clinical trial in
patients on standard treatment. J. Psychopharmacol. 26 (9), 1185–1193.
Chen, S.J., Chao, Y.L., Chen, C.Y., Chang, C.M., Wu, E.C., Wu, C.S., Yeh, H.H., Chen, C.H., Tsai,
H.J., 2012a. Prevalence of autoimmune diseases in in-patients with schizophrenia:
nationwide population-based study. Br. J. Psychiatry 200 (5), 374–380.
Chen, S.L., Lee, S.Y., Chang, Y.H., Chen, S.H., Chu, C.H., Tzeng, N.S., Lee, I.H., Chen, P.S.,
Yeh, T.L., Huang, S.Y., Yang, Y.K., Lu, R.B., 2012b. Inﬂammation in patients with
schizophrenia: the therapeutic beneﬁts of risperidone plus add-on dextromethor-
phan. J. NeuroImmune Pharm. 7 (3), 656–664.
Clerici, M., Arosio, B., Mundo, E., Cattaneo, E., Pozzoli, S., Dell'osso, B., Vergani, C.,
Trabattoni, D., Altamura, A.C., 2009. Cytokine polymorphisms in the pathophysiology
of mood disorders. CNS Spectr. 14 (8), 419–425.
Diez-Ruiz, A., Tilz, G.P., Zangerle, R., Baier-Bitterlich, G., Wachter, H., Fuchs, D., 1995.
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur.
J. Haematol. 54 (1), 1–8.
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L.,
2010. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (5),
446–457.
Drexhage, R., Knijff, E., Padmos, R., Heul-Nieuwenhuijzen, L., Beumer, W., Versnel, M.,
Drexhage, H., 2010. The mononuclear phagocyte system and its cytokine inﬂam-
matory networks in schizophrenia and bipolar disorder. Expert. Rev. Neurother.
10 (1), 59–76.
Drexhage, R.C., Weigelt, K., van Beveren, N., Cohen, D., Versnel, M.A., Nolen, W.A.,
Drexhage, H.A., 2011. Immune and neuroimmune alterations in mood disorders
and schizophrenia. Int. Rev. Neurobiol. 101, 169–201.
Drzyzga, L., Obuchowicz, E., Marcinowska, A., Herman, Z.S., 2006. Cytokines in schizo-
phrenia and the effects of antipsychotic drugs. Brain Behav. Immun. 20 (6), 532–545.
Eaton, W.W., Pedersen, M.G., Nielsen, P.R., Mortensen, P.B., 2010. Autoimmune diseases,
bipolar disorder, and non-affective psychosis. Bipolar Disord. 12 (6), 638–646.
Eberhard, J., Levander, S., Lindstrom, E., 2009. Remission in schizophrenia: analysis in a
naturalistic setting. Compr. Psychiatry 50 (3), 200–208.
Erbaægci, A.B., Herken,H., Kèoylèuoglu, O., Yilmaz, N., Tarakðcioglu,M., 2001. Serum IL-1beta,
sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relationwith symptomatology
and responsiveness to risperidone treatment. Mediat. Inﬂamm. 10 (3), 109–115.
Freudenreich, O., Brockman, M.A., Henderson, D.C., Evins, A.E., Fan, X., Walsh, J.P., Goff, D.C.,
2010. Analysis of peripheral immune activation in schizophrenia using quantitative
reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res. 176 (2–3),
99–102.
Gabay, C., Smith, M.F., Eidlen, D., Arend, W.P., 1997. Interleukin 1 receptor antagonist
(IL-1Ra) is an acute-phase protein. J. Clin. Invest. 99 (12), 2930–2940.
Goldstein, B.I., Kemp, D.E., Soczynska, J.K., McIntyre, R.S., 2009. Inﬂammation and the
phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder:
a systematic review of the literature. J. Clin. Psychiatry 70 (8), 1078–1090.
Gomez-Santos, C., Francisco, R., Gimenez-Xavier, P., Ambrosio, S., 2007. Dopamine in-
duces TNFalpha and TNF-R1 expression in SH-SY5Y human neuroblastoma cells.
NeuroReport 18 (16), 1725–1728.
Goodwin, F.K., Jamison, K.R., 1990. Manic-depressive Illness. Oxford University Press,
New York.
Greenberg, G.A., Rosenheck, R.A., 2005. Using the GAF as a national mental health out-
come measure in the Department of Veterans Affairs. Psychiatr. Serv. 56 (4),
420–426.
Gu, Y., Zeleniuch-Jacquotte, A., Linkov, F., Koenig, K.L., Liu, M., Velikokhatnaya, L., Shore,
R.E., Marrangoni, A., Toniolo, P., Lokshin, A.E., Arslan, A.A., 2009. Reproducibility of
serum cytokines and growth factors. Cytokine 45 (1), 44–49.
Harrison, P.J., Weinberger, D.R., 2005. Schizophrenia genes, gene expression, and
neuropathology: on the matter of their convergence. Mol. Psychiatry 10 (1),
40–68 (image 45).
Hope, S., Melle, I., Aukrust, P., Steen, N.E., Birkenaes, A.B., Lorentzen, S., Agartz, I.,
Ueland, T., Andreassen, O.A., 2009. Similar immune proﬁle in bipolar disorder
and schizophrenia: selective increase in soluble tumor necrosis factor receptor I
and von Willebrand factor. Bipolar Disord. 11 (7), 726–734.
Hope, S., Melle, I., Aukrust, P., Agartz, I., Lorentzen, S., Steen, N.E., Djurovic, S., Ueland, T.,
Andreassen, O.A., 2010. Osteoprotegerin levels in patients with severe mental dis-
orders. J. Psychiatry Neurosci. 35 (5), 304–310.
Hope, S., Dieset, I., Agartz, I., Steen, N.E., Ueland, T., Melle, I., Aukrust, P., Andreassen,
O.A., 2011. Affective symptoms are associated with markers of inﬂammation and
immune activation in bipolar disorders but not in schizophrenia. J. Psychiatr. Res.
45 (12), 1608–1616.
Hsuchou, H., Kastin, A.J., Mishra, P.K., Pan, W., 2012. C-reactive protein increases bbb
permeability: implications for obesity and neuroinﬂammation. Cell. Physiol.
Biochem. 30 (5), 1109–1119.
42 S. Hope et al. / Schizophrenia Research 145 (2013) 36–42Jabben, N., Arts, B., Krabbendam, L., van Os, J., 2009. Investigating the association be-
tween neurocognition and psychosis in bipolar disorder: further evidence for the
overlap with schizophrenia. Bipolar Disord. 11 (2), 166–177.
Jiang, H., Hampel, H., Prvulovic, D., Wallin, A., Blennow, K., Li, R., Shen, Y., 2011. Elevated
CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive
impairment and patients with Alzheimer's disease. Mol. Neurodegener. 6, 69.
Kay, S.R., Fiszbein, A., Opler, L.A., 1987. The positive and negative syndrome scale
(PANSS) for schizophrenia. Schizophr. Bull. 13 (2), 261–276.
Kop, W.J., Weissman, N.J., Zhu, J., Bonsall, R.W., Doyle, M., Stretch, M.R., Glaes, S.B.,
Krantz, D.S., Gottdiener, J.S., Tracy, R.P., 2008. Effects of acute mental stress and
exercise on inﬂammatory markers in patients with coronary artery disease and
healthy controls. Am. J. Cardiol. 101 (6), 767–773.
Koprich, J.B., Reske-Nielsen, C., Mithal, P., Isacson, O., 2008. Neuroinﬂammation medi-
ated by IL-1beta increases susceptibility of dopamine neurons to degeneration in
an animal model of Parkinson's disease. J. Neuroinﬂammation 5, 8.
Kunz, M., Cereser, K.M., Goi, P.D., Fries, G.R., Teixeira, A.L., Fernandes, B.S., Belmonte-de-
Abreu, P.S., Kauer-Sant'Anna, M., Kapczinski, F., Gama, C.S., 2011. Serum levels of
IL-6, IL-10 and TNF-alpha in patients with bipolar disorder and schizophrenia:
differences in pro- and anti-inﬂammatory balance. Rev. Bras. Psiquiatr. 33 (3),
268–274.
Mata, I., Crespo-Facorro, B., Pâerez-Iglesias, R., Carrasco-Marâin, E., Arranz, M.J., Pelayo-
Terâan, J.M., Leyva-Cobâian, F., Vâazquez-Barquero, J.L., 2006. Association between
the interleukin-1 receptor antagonist gene and negative symptom improvement
during antipsychotic treatment. American journal of medical genetics. Part B:
Neuropsychiatr. Genet. 141B (8), 939–943.
McAfoose, J., 2009. Evidence of a cytokine model for cognitive function. Neurosci.
Biobehav. Rev. 33 (3), 355–366.
Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., 2011. Meta-analysis of
cytokine alterations in schizophrenia: clinical status and antipsychotic effects.
Biol. Psychiatry 70 (7), 663–671.
Nahman, S., Belmaker, R.H., Azab, A.N., 2012. Effects of lithium on lipopolysaccharide-
induced inﬂammation in rat primary glia cells. Innate Immun. 18 (3), 447–458.
Norman, G.J., Karelina, K., Morris, J.S., Zhang, N., Cochran, M., Courtney DeVries, A.,
2010. Social interaction prevents the development of depressive-like behavior
post nerve injury in mice: a potential role for oxytocin. Psychosom. Med. 72 (6),
519–526.
Orre, I.J., Murison, R., Dahl, A.A., Ueland, T., Aukrust, P., Fossêa, S.D., 2009. Levels of
circulating interleukin-1 receptor antagonist and C-reactive protein in long-term
survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav.
Immun. 23 (6), 868–874.
Prasad, K.M., Eack, S.M., Keshavan, M.S., Yolken, R.H., Iyengar, S., Nimgaonkar, V.L.,
2012. Antiherpes virus-speciﬁc treatment and cognition in schizophrenia: a test-
of-concept randomized double-blind placebo-controlled trial. Schizophr. Bull.
(Epub ahead of print).
Prata, D.P., Mechelli, A., Fu, C.H., Picchioni, M., Kane, F., Kalidindi, S., McDonald, C., Howes,
O., Kravariti, E., Demjaha, A., Toulopoulou, T., Diforti, M., Murray, R.M., Collier, D.A.,
McGuire, P.K., 2009. Opposite effects of catechol-O-methyltransferase Val158Met
on cortical function in healthy subjects and patients with schizophrenia. Biol.
Psychiatry 65 (6), 473–480.Raﬁq, S., Stevens, K., Hurst, A.J., Murray, A., Henley, W., Weedon, M.N., Bandinelli, S.,
Corsi, A.M., Guralnik, J.M., Ferruci, L., Melzer, D., Frayling, T.M., 2007. Common ge-
netic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is
associated with altered circulating IL-1RA levels. Genes Immun. 8 (4), 344–351.
Ringen, P.A., Melle, I., Birkenaes, A.B., Engh, J.A., Faerden, A., Jonsdottir, H., Nesvag, R.,
Vaskinn, A., Friis, S., Larsen, F., Opjordsmoen, S., Sundet, K., Andreassen, O.A., 2008.
Illicit drug use in patients with psychotic disorders compared with that in the general
population: a cross-sectional study. Acta Psychiatr. Scand. 117 (2), 133–138.
Rohleder, N., Wolf, J.M., Herpfer, I., Fiebich, B.L., Kirschbaum, C., Lieb, K., 2006. No
response of plasma substance P, but delayed increase of interleukin-1 receptor
antagonist to acute psychosocial stress. Life Sci. 78 (26), 3082–3089.
Santor, D.A., Ascher-Svanum, H., Lindenmayer, J.P., Obenchain, R.L., 2007. Item re-
sponse analysis of the Positive and Negative Syndrome Scale. BMC Psychiatry 7, 66.
Schmitt, A., Bertsch, T., Tost, H., Bergmann, A., Henning, U., Klimke, A., Falkai, P., 2005. In-
creased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic
patients on stable antipsychotic medication. Neuropsychiatr. Dis. Treat. 1 (2), 171–177.
Sirota, P., Meiman, M., Herschko, R., Bessler, H., 2005. Effect of neuroleptic administra-
tion on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in
schizophrenic patients. Psychiatry Res. 134 (2), 151–159.
Sommer, I.E., de Witte, L., Begemann, M., Kahn, R.S., 2012. Nonsteroidal anti-
inﬂammatory drugs in schizophrenia: ready for practice or a good start? A meta-
analysis. J. Clin. Psychiatry 73 (4), 414–419.
Spulber, S., Mateos, L., Oprica, M., Cedazo-Minguez, A., Bartfai, T., Winblad, B., Schultzberg,
M., 2009. Impaired long termmemory consolidation in transgenic mice overexpressing
the human soluble form of IL-1ra in the brain. J. Neuroimmunol. 208 (1–2), 46–53.
Tchelingerian, J.L., Quinonero, J., Booss, J., Jacque, C., 1993. Localization of TNF alpha and
IL-1 alpha immunoreactivities in striatal neurons after surgical injury to the hippo-
campus. Neuron 10 (2), 213–224.
Vistoropsky, Y., Ermakov, S., Toliat, M.R., Troﬁmov, S., Altmuller, J., Malkin, I., Nurnberg,
P., Livshits, G., 2010. Genetic determinants of circulating levels of tumor necrosis
factor receptor II and their association with TNF-RII gene polymorphisms. Cytokine
51 (1), 28–34.
Watanabe, Y., Someya, T., Nawa, H., 2010. Cytokine hypothesis of schizophrenia
pathogenesis: evidence from human studies and animal models. Psychiatry Clin.
Neurosci. 64 (3), 217–230.
Williams, H.J., Craddock, N., Russo, G., Hamshere, M.L., Moskvina, V., Dwyer, S., Smith, R.L.,
Green, E., Grozeva, D., Holmans, P., Owen, M.J., O'Donovan, M.C., 2011. Most genome-
wide signiﬁcant susceptibility loci for schizophrenia and bipolar disorder reported to
date cross-traditional diagnostic boundaries. Hum. Mol. Genet. 20 (2), 387–391.
Wirgenes, K.V., Djurovic, S., Sundet, K., Agartz, I., Mattingsdal, M., Athanasiu, L., Melle,
I., Andreassen, O.A., 2010. Catechol O-methyltransferase variants and cognitive
performance in schizophrenia and bipolar disorder versus controls. Schizophr.
Res. 122 (1–3), 31–37.
Yirmiya, R., Goshen, I., 2011. Immune modulation of learning, memory, neural plasticity
and neurogenesis. Brain Behav. Immun. 25 (2), 181–213.
Zhang, X.Y., Cao, L.Y., Song, C., Wu, G.Y., Chen da, C., Qi, L.Y., Wang, F., Xiu, M.H., Chen, S.,
Zhang, Y., Lu, L., Kosten, T.A., Kosten, T.R., 2008. Lower serum cytokine levels in
smokers than nonsmokers with chronic schizophrenia on long-term treatment
with antipsychotics. Psychopharmacology 201 (3), 383–389.
